Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by fossi_2002on Oct 17, 2023 6:53am
128 Views
Post# 35686681

The small-cap seasonality is to blame for the misery.

The small-cap seasonality is to blame for the misery.
It's always the others fault!!!

First, the 3rd quarter of 2022 was only an exception - that was completely negated, because otherwise the year 2022 was very good.
Then came the 4th quarter of 2022 and that was ignored - because yes the overall year 2022 was still very good.
Then came the 1st. quarter 2023 with a loss closing - but an increase in salaries from 217' to 361'- and an increase in Board of Directors compensation from 59`to 271'!!!! O Ronnie how much are you worth to us!!!

Then came the 2nd quarter 2023 with the biggest loss in years (minus 1.1 mill). Now J&J was to blame.

If it wasn't those factors, it was the bad biotech sector. Now Proph... found a new culprit for the misery - it's the small-cap-seasonality.

We've already heard from you that - unlike us - you have a particularly high IQ. But that you think we are so stupid that we don't realize what kind of method is behind it, is really brazen.
You also know who runs the company, and there is an appropriate phrase from the vernacular: "the fish stinks from the head".





<< Previous
Bullboard Posts
Next >>